gouthamnarla
@gouthamnarla.bsky.social
physician scientist, professor of medicine, drug hunter, biotech entrepreneur, father, husband, lover of food, wine, and golf
Abstract B051: Discovery of SW-3431, a first-in-class molecular glue activator with potent and selective anti-tumor activity in PPP2R1A mutant cancers url: aacrjournals.org/mct/article/...
Abstract B051: Discovery of SW-3431, a first-in-class molecular glue activator with potent and selective anti-tumor activity in PPP2R1A mutant cancers
AbstractUterine cancer is the only cancer type for which survival has fallen in the past four decades. This past year, uterine cancer deaths surpassed ovarian cancer for the first time: making uterine...
aacrjournals.org
October 23, 2025 at 12:31 PM
Abstract B051: Discovery of SW-3431, a first-in-class molecular glue activator with potent and selective anti-tumor activity in PPP2R1A mutant cancers url: aacrjournals.org/mct/article/...
Reposted by gouthamnarla
Our new paper describing how mutations to the PP2A gene PPP2R1A drive high-grade uterine cancers is out now in this issue of Cancer Research by @theaacr.bsky.social
aacrjournals.org/cancerres/ar...
aacrjournals.org/cancerres/ar...
Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Elevated IGFBP2 secretion by uterine cancer cells with heterozygous PPP2R1A mutations supports tumor progression and confers a vulnerability to IGFBP2/IGF1R inhibition as a therapeutic approach for th...
aacrjournals.org
February 5, 2025 at 5:19 PM
Our new paper describing how mutations to the PP2A gene PPP2R1A drive high-grade uterine cancers is out now in this issue of Cancer Research by @theaacr.bsky.social
aacrjournals.org/cancerres/ar...
aacrjournals.org/cancerres/ar...
Reposted by gouthamnarla
Molecular Glue Boosts PP2A, Overcoming Resistance to RAS/MAPK Inhibitors in KRAS-Mutant Lung Cancer, Enhancing Survival Rates.
by Raines B, Tseng-Rogenski S (...) Narla G et 14 al. in J Clin Invest #MedSky
👉 get more here
📖 read the article: https://www.jci.org/articles/view/193790
by Raines B, Tseng-Rogenski S (...) Narla G et 14 al. in J Clin Invest #MedSky
👉 get more here
📖 read the article: https://www.jci.org/articles/view/193790
October 23, 2025 at 4:34 AM
Molecular Glue Boosts PP2A, Overcoming Resistance to RAS/MAPK Inhibitors in KRAS-Mutant Lung Cancer, Enhancing Survival Rates.
by Raines B, Tseng-Rogenski S (...) Narla G et 14 al. in J Clin Invest #MedSky
👉 get more here
📖 read the article: https://www.jci.org/articles/view/193790
by Raines B, Tseng-Rogenski S (...) Narla G et 14 al. in J Clin Invest #MedSky
👉 get more here
📖 read the article: https://www.jci.org/articles/view/193790
Exciting new finding about the role of PP2A molecular glues in overcoming resistant to broad classes of MAPK inhibitors in KRAS driven cancers
JCI - A PP2A molecular glue overcomes ras/mapk inhibitor resistance in kras-mutant non-small cell lung cancer www.jci.org/articles/vie...
JCI - A PP2A molecular glue overcomes ras/mapk inhibitor resistance in kras-mutant non-small cell lung cancer www.jci.org/articles/vie...
JCI -
A PP2A molecular glue overcomes ras/mapk inhibitor resistance in kras-mutant non-small cell lung cancer
www.jci.org
October 21, 2025 at 2:00 PM
Exciting new finding about the role of PP2A molecular glues in overcoming resistant to broad classes of MAPK inhibitors in KRAS driven cancers
JCI - A PP2A molecular glue overcomes ras/mapk inhibitor resistance in kras-mutant non-small cell lung cancer www.jci.org/articles/vie...
JCI - A PP2A molecular glue overcomes ras/mapk inhibitor resistance in kras-mutant non-small cell lung cancer www.jci.org/articles/vie...